NYSE:TARO
Taro Pharmaceutical Industries Ltd Stock News
$42.40
-0.0800 (-0.188%)
At Close: Apr 26, 2024
Taro (TARO) is on the Move, Here's Why the Trend Could be Sustainable
10:31am, Wednesday, 20'th Dec 2023
Taro (TARO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our short
All You Need to Know About Taro (TARO) Rating Upgrade to Strong Buy
01:32pm, Wednesday, 01'st Nov 2023
Taro (TARO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
08:53am, Monday, 09'th Oct 2023
Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.
Taro Pharmaceutical: Potential Value In Sun Pharma Offer
02:41pm, Friday, 02'nd Jun 2023
Taro received a $38/share offer from Sun Pharma last month. The deal represents a decent premium to the firm's market value at the time and a 12% premium to my estimate of fair value. Further insights
Why Shares of Taro Pharmaceutical Are Rising Tuesday
12:25pm, Tuesday, 30'th May 2023
Taro saw rising revenue in the fourth quarter but falling net income. Sun Pharmaceutical already owns 78.5% of Taro's shares.
Taro to Release Full Year Results on May 23, 2023
04:46pm, Thursday, 18'th May 2023
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2023, after the close of
Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold
12:18am, Friday, 24'th Feb 2023
Taro Pharmaceutical's quarterly numbers came in with very thin growth at the operating and bottom-lines given the impact from settlement charges. Price erosion in its U.S. generics business continues
Francisco Garcia Parames' Cobas Funds 4th-Quater Letter
06:01pm, Wednesday, 22'nd Feb 2023
Dear Investor:
Taro Pharmaceutical (TARO) Lags Q3 Earnings and Revenue Estimates
08:19pm, Tuesday, 24'th Jan 2023
Taro (TARO) delivered earnings and revenue surprises of -78.16% and 14.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Taro to Release Third Quarter Results on January 24, 2023
05:02pm, Thursday, 19'th Jan 2023
HAWTHORNE, N.Y.--( BUSINESS WIRE )--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after
Taro Pharmaceutical (TARO) Reports Q2 Loss, Misses Revenue Estimates
09:04pm, Thursday, 27'th Oct 2022
Taro (TARO) delivered earnings and revenue surprises of -108.33% and 18.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Taro to Release Second Quarter Results on October 27, 2022
12:37pm, Monday, 24'th Oct 2022
HAWTHORNE, N.Y.
Taro Pharmaceutical (TARO) Lags Q1 Earnings Estimates
08:54pm, Wednesday, 27'th Jul 2022
Taro (TARO) delivered earnings and revenue surprises of -56.47% and 4.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Taro to Release First Quarter Results on July 27, 2022
03:37pm, Tuesday, 26'th Jul 2022
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the c
Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card
08:27pm, Wednesday, 13'th Jul 2022
Based on the current long-term trend, shares look like they will test long-term support. We expect support to hold there based on the company's strong earnings power and clean balance sheet.
